S-28463 (also known as R-848 or VML-600) is an immune response modifier, discovered by 3M. It is an analog of the
drug imiquimod, a cream used to treat viral warts. 3M partnered with Vanguard Medica to develop it into an oral treatment
for hepatitis C. Animal studies have demonstrated that imiquimod may increase the level of endogenous interferon.
Currently there is no proof S-28463 can increase the amount of interferon in humans to therapeutic levels (